Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5Head & Neck 4Thoracic 3Lymphoid 3Breast 3Other hematologic neoplasm 2Gynecologic 2Plasma cell 1Other neoplasm 1Myeloid 1Genitourinary 1

Conditions

Carcinoma, Renal Cell 1Agnosia 1

Interventions

Docetaxel 390pembrolizumab 325Prednisone 284Gemcitabine 273enzalutamide 254Radiotherapy 251Nivolumab 247Magnetic Resonance Spectroscopy 247Cisplatin 209Abiraterone Acetate 197Radiosurgery 184Leuprolide 182Sunitinib 169Carboplatin 161bicalutamide 148Goserelin 145Androgen Antagonists 142Specimen Handling 138Ipilimumab 128Paclitaxel 125Cyclophosphamide 116acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110Bevacizumab 109Everolimus 107apalutamide 98cabozantinib 97abiraterone 97Sorafenib 97atezolizumab 96Radiation 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Epinephrine × Genitourinary × Clear all
NCT07092566 2026-01-20

R.E.C.K vs Exparel in Robotic Nephrectomy

Wake Forest University Health Sciences

Phase 3 Recruiting
170 enrolled
Genitourinary

Agnosia, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡